 |
2004
OMIG, Abstract 9
OMIG
Main Page | 2004
Abstracts | < Previous
| Next >
Comparison
of In-Vitro Sensitivity Rates of the Ophthalmic Fluoroquinolones
and Vancomycin Against Propionibacterium acnes Ocular Isolates
M Shah, D Ritterband, TL Kajura, W Perez, D Shapiro, JA Seedor,
R Koplin. New York Eye and Ear Infirmary Department of Ophthalmology,
New York, New York
Purpose:
To study the in-vitro susceptibility profiles of the ophthalmic
fluoroquinolone agents and vancomycin against Propionibacterium
acnes (P. acnes), a frequent cause of post-cataract chronic
endophthalmitis.
Methods: 42 P. acnes ocular isolates archived
at the New York Eye and Ear Infirmary (NYEEI) from cases of corneal
ulcer (24), chronic endophthalmitis (12), corneal rim culture (7),
and an infected scleral buckle (1) were tested for in vitro susceptibility
against vancomycin, moxifloxacin, gatifloxacin, levofloxacin, ofloxacin
and ciprofloxacin. P. acnes isolates were subcultured on
Brucella Agar - 5% sheeps-blood fortified with Vitamin K and Hemin.
The subcultures was inoculated into anaerobic broth to make a 1.0
McFarland turbidity. The suspension was vortexed and replated on
the Brucella media. Each culture was incubated at 35° C for
24-48 hours in anaerobic conditions. E-test strips were used to
generate MIC values for ciprofloxacin, ofloxacin, levofloxacin,
gatifioxacin, moxifloxacin, and vancomycin.
Results: 40 P. acnes isolates were sensitive
to all antibiotics. Two P. acnes isolates (1 ulcer, 1 rim)
were resistant to all flouroquinolone (FQ) agents but sensitive
to vancomycin. The mean MIC for 40 P. acnes isolates sensitive
to the (FQ) agents was in descending order ofloxacin (.87), ciprofloxacin
(.45), levofloxacin(.35), gatifloxacin (.16), moxifloxacin (.l4).
The mean MIC for the 40 FQ-sensitive P.acnes isolates for
vancomycin was (.97).
Conclusions: The fourth generation fluoroquinolone
agents moxifloxacin and gatifloxacin demonstrate excellent in vitro
sensitivity profiles with low MIC's against almost all P. acnes
isolates. The potential use of the moxifloxacin or gatifloxacin
in the intraocular treatment of these organisms warrants further
study.
Disclosure
code: F
OMIG
Main Page | 2004
Abstracts | < Previous
| Next >
|
|
|
